Vitro Diagnostics Inc. (fka VODG)

[Potse]

Corporate Overview...clinical trials, MSC-Gro, etc....

VODG updated the "Corporate Overview" section of its website a couple of days ago. The update provides some information on the two clinical trials that VODG is planning (US-based human TBI/concussion treatment, and skeletal/muscular treatment of horses).

The recent bulk order/business from a foreign customer is mentioned. VODG also expresses interest in collaborating on additional cell-based assays for toxicology screening of drug candidates in the cardiovascular, neural and kidney markets. These new assays would use differentiated cells developed by VODG.

So there should be a number of potentially interesting developments occurring over the remainder of 2015 and into early 2016 that could lead to some sustained (or semi-sustained) price movement upward. At the very least, I think the chances are fairly good of seeing some pretty nice tradeable swings/spikes in the share price over the next 6-9 months.......

Our current operational strategy involves expanding market penetration of our MSC research products together with development of products and services to support clinical applications of stem cells in treatment of animal and human conditions. Our MSC-Gro™ cell culture media is now available as Clinical Grade material for use in MSC expansion prior to transplantation. There are several clinical trials ongoing now using MSC-based treatments of a variety of conditions. These studies often require expansion of stem cells prior to transplantation. Our Clinical Grade MSC-Gro™ has numerous competitive advantages for use in this application. We have recently established bulk distribution of Clinical Grade MSC-Gro™ to an off-shore customer and we intend to expand this business considerably. We are also pursuing collaboration involving the use of select terminally differentiated cells developed by Vitro Biopharma for use in preclinical toxicology screening of drug candidates. Our cells targeting this market include MSC-derived cardiomyocytes, MSC-derived neurons including a-motorneurons and dopaminergic neurons together with Nephron Progenitor Cell (NPC)-derived PTECs (proximal tubule epithelial cells) & podocytes. Our NPCs are initially derived from MSCs prior to terminal differentiation into the functional cells of the kidney. Thus our products enable cell-based assays of cardiovascular, neural and kidney toxicity. When combined with hepatocytes, this provides an in-vitro ADMET screening process that not only determines direct drug toxicity but also allows determination of the toxicity of drug metabolites.

We are establishing clinical trials for the treatment of neurological conditions. This is supported by numerous studies suggesting stem cell efficacy in the treatment of stroke, ALS, and traumatic brain injury/concussion. We are nearing approval of our first US-based clinical trial for treatment of TBI/concussion and hope to begin patient recruitment during the summer of 2015. TBI affects 1.5 million people a year in the US only and lacks effective therapy, now relying predominantly on physical therapy/rehabilitation. Our trial will test novel diagnostics for recovery of brain function by the activation of stem cells residing within the brain.

We also have a proprietary cell line with application to treatment of skeletal muscular conditions in horses. This cell line has now advanced through all pre-clinical studies and we anticipate on-set of clinical trials of this cell line in late 2015. We are targeting tendonitis treatment as the primary indication. Tendonitis is common among sporting horses and often leads to discontinuation of racing or other competition during to lack of functional recovery. Stem cell therapy has been shown to result in functional recovery and resumption of competitive activities.

http://vitrobiopharma.com/home/about/